Insider Insights
12.10.2022
France: Implications for Pharma of the proposed So...

Leem report the changes set out by the Government will heighten the difficulties already being faced...

Read more
Articles
21.09.2022
Pricing and reimbursement of cell and gene therapi...

Introduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...

Read more
Articles
21.09.2022
Are payers willing to pay for innovation for gene ...

We look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...

Read more
Insider Insights
23.08.2022
Inflation reduction act aims to reduce healthcare

The legislation is an updated, smaller version of The Build Back Better Act (BBBA) which the US Sena...

Read more
Insider Insights
22.08.2022
HAS announces changes to health evaluation

The Haute Autorité de Santé (HAS), recently announced changes to the conditions in which a drug wi...

Read more
Insider Insights
28.07.2022
Federal cabinet approves Lauterbachs draft GKV

One notable change from the last released updated bill was the removal of the solidarity levy of 2 b...

Read more
News
14.07.2022
PMA Insights: Week 28

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
13.07.2022
Big pharmas lose out in Chinas latest round of dru

AZ has warned its China revenues will decline mid-single-digit percentage in 2022 after years of dou...

Read more
Insider Insights
11.07.2022
New pharmaceutical updated cost containment measur

This updated bill contains some similar measures to those proposed in March as well as some addition...

Read more
Insider Insights
23.06.2022
AIFA reorganisation delayed again

It is widely expected that the reform will entail the unification of the CTS and the CPR into one bo...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.